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Background: Up to date treatment of ST elevation myocardial infarction
(STEMI) has been based on as early as possible reperfusion that can be
achieved by either primary angioplasty (PAMI) or thrombolysis. 
Predictors of mortality of these two strategies may not be similar. The aim
of this analysis was to identify mortality predictors in STEMI patients (pts)
according to the reperfusion strategy.
Methods: A total of 1353 pts admitted for acute myocardial infarction
(AMI) between January 1995 and April 2011 were included in our MIRAMI
(MonastIR Acute Myocardial Infarction) registry. Reperfusion therapy was
given to 788 (58.2%) pts. Because of lacking data, 117 were excluded, the
remaining 671 pts were considered for this analysis: 372 pts received throm-
bolytics and 299 underwent primary angioplasty. In each group, an univariate
then a multivariate logistic regression analysis was used to evaluate the impact
on mortality of the following factors: age, sex, hypertension, diabetes,
smoking, infarct location, Killip class, time to treatment (TTT), hemoglobin
and creatinin serum levels.
Results: Among the tested parameters, only four were identified to be
independent predictors of mortality by multivariate analysis as shown below:
Conclusion: In our MIRAMI registry, regardless of the reperfusion
strategy, mortality predictors were: time to treatment > 6 hours, heart failure
and renal impairment. Hemoglobin blood level less than 12g/dl was an inde-
pendent predictor only in the primary angioplasty group.
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Background. Clopidogrel is an antiplatelet drug that requires bioactivation
to its active metabolite to demonstrate its antiplatelet effect. Formation of the
active metabolite involves multiple cytochrome P450 enzymes, with
CYP2C19 playing an important role. Clopidogrel is often co-administered
with proton pump inhibitors (PPIs) to decrease gastro intestinal-tract bleeding.
The aim of this study was to assess the association between the loss-of-
function cytochrome P450 2C19 (CYP2C19)*2 variant, the use of proton
pump inhibitors (PPIs) and ischemic outcomes (major adverse cardiovascular
events [MACE]) in patients treated with clopidogrel.
Methods. Between May 2009, and september 2010, 100 patients who
underwent a percutaneous coronary intervention (PCI) and were exposed to
clopidogrel treatment for at least one month, were enrolled in our study. They
underwent CYP2C19*2 determination. The primary endpoint was a composite
of death, myocardial infarction, and urgent coronary revascularisation occur-
ring during exposure to clopidogrel.
Results. 75% of our patients were on PPIs in the hospital phase distributed
equally between the two groups non mutated and mutated (74% vs 78.3%
p=0.68). The use of PPIs in the hospital phase did not cause a significant
increase in the occurrence of MACE (p=0.23).
In the group of patients on PPIs, no statistically significant difference was
observed regarding the occurrence of intra hospital MACE according to genetic
profile (5, 3% in the non mutated group versus 5,6% in the mutated group).
Conclusion. The present study provides further supportive evidence to
indicate that PPIs can be used safely in patients taking clopidogrel. Although
omeprazole might attenuate some of the in vitro antiplatelet effects of clopi-
dogrel, convincing evidence is currently lacking to indicate that this combina-
tion places patients at increased risk of harm.
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Introduction. To explore the role of genetic variant of angiotensinogen
(AGT) M235T as an independent risk factor for acute myocardial infarction
(AMI) and to investigate the possible association with the severity of coronary
artery disease (CAD), estimated on the basis of the number of coronary ste-
noses and critical arterial occlusions. 
Patients and methods. 123 AMI patients compared to 144 healthy
controls. AGT genotypes were determined by PCR method.
Results. A significant association was found between AGT M235T poly-
morphism and AMI (p=0.021). By logistic regression, the TT genotype
appeared to confer 1.9-fold increased risk for AMI in both the univariate and
the multivariate model. The frequencies of TT genotype and T allele increased
with the number of stenoses in coronary vessels. Moreover, the TT genotype
and the T allele were more frequent in the subgroup of patients with stenoses
in at least four coronary vessels than in other patients including subjects with
one to three vessel disease. Furthermore, the TT genotype and the T allele
were significantly more frequent in patients with critical arterial occlusions
(>90%) than in subjects without critical stenoses. 
Conclusions. The AGT M235T polymorphism associates with AMI risk
and influences CAD severity. 
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BMI
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Antihypertensive therapy (%)
Hypolipemic therapy (%)
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LV Ej. Fraction >50% (%)
Anti-GP IIB IIIA before
Number of stents/procedure
Number of segments/procedure
Stent length/procedure
Hospital mortality (%)
64.8
29.8
26.0
49.5
39.6
10.9
71.6
5.2
1.5
1.6
22.8
2.5
65  
29.9
21.0
57.2
51.1
16.3
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10.5
1.7
1.7
23.6
1.1
NS
NS
NS
=0.05
<0.01
<0.05
=0.05
=0.01
=0.01
NS
NS
NS
Stent thrombosis (%) 1 y.
4 y. 
Repeat TLR (%) 1 y.
4 y.
Overall death (%) 1 y.
4 y. 
5,0
7.5
14.9
22.5
9,0
17.0
5.1
7.1
7.1
16.0
9.0
24.0
NS
=0.09
NS
TTT>6 hours Killip class ≥2 Creatinin 
>150μmol/l
Hemoglobin
<12g/dl
Thrombolysis 
group
p=0.03
OR=3.28
p=0.0001
OR:2.9 to 17.17
p=0.014
OR=4.39
NS
PAMI group p=0.036
OR=2.8
p<0.001
OR: 4.41 to 19.21
p=0.006
OR=4.93
p=0.003
OR=3.96
